A Phase 1/2a Multicenter Open-Label First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors

Go Back to All Clinical Trials

A Phase 1/2a Multicenter Open-Label First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors

Brief description of study

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303 in subjects with advanced solid tumors that express HER2.

Clinical Study Identifier: s22-00655

ClinicalTrials.gov Identifier: NCT05150691

Principal Investigator: Whitfield B. Growdon.

Other Investigators: Kathleen M Lutz, Bhavana Pothuri, Kent Chan, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Carol M Lee, Jonathan B Kahn, Gabrielle Fridman, Fabia Brisard Pierrot, Cindy Corbo, Kelly A Levine, Olivia Richardson Khouri, Victoria Helen Dowd, Leslie R Boyd.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies